{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:05:52Z","timestamp":1772892352838,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["K2023005"],"award-info":[{"award-number":["K2023005"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11307-025-02070-9","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:26:36Z","timestamp":1765740396000},"page":"127-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of a Novel TIM-3 Targeting Peptides Probe to Indicate the Immunomodulation of SBRT Combined with Anti-TIM-3 Therapy in HCC"],"prefix":"10.1007","volume":"28","author":[{"given":"Muhao","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-5235","authenticated-orcid":false,"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"issue":"10127","key":"2070_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391(10127):1301\u20131314. https:\/\/doi.org\/10.1016\/s0140-6736(18)30010-2","journal-title":"Lancet"},{"key":"2070_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/s0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A (2022) Hepatocellular carcinoma. Lancet 400:1345\u20131362. https:\/\/doi.org\/10.1016\/s0140-6736(22)01200-4","journal-title":"Lancet"},{"key":"2070_CR3","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/s0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389:2492\u20132502. https:\/\/doi.org\/10.1016\/s0140-6736(17)31046-2","journal-title":"Lancet"},{"key":"2070_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-018-0667-4","volume":"11","author":"F Liu","year":"2018","unstructured":"Liu F, Liu Y, Chen Z (2018) Tim-3 expression and its role in hepatocellular carcinoma. J Hematol Oncol 11:126. https:\/\/doi.org\/10.1186\/s13045-018-0667-4","journal-title":"J Hematol Oncol"},{"key":"2070_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/cji.0000000000000122","volume":"39","author":"J Liu","year":"2016","unstructured":"Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X et al (2016) Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic\/tumor vaccines. J Immunother 39:171\u2013180. https:\/\/doi.org\/10.1097\/cji.0000000000000122","journal-title":"J Immunother"},{"issue":"5","key":"2070_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317698352","volume":"39","author":"Z Li","year":"2017","unstructured":"Li Z, Liu X, Guo R, Wang P (2017) TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. Tumour Biol 39(5):1010428317698352. https:\/\/doi.org\/10.1177\/1010428317698352","journal-title":"Tumour Biol"},{"key":"2070_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ et al (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6:1245\u20131252. https:\/\/doi.org\/10.1038\/ni1271","journal-title":"Nat Immunol"},{"issue":"4","key":"2070_CR8","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23849","volume":"2","author":"K Sakuishi","year":"2013","unstructured":"Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Teng MWL, Anderson AC (2013) TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2(4):e23849. https:\/\/doi.org\/10.4161\/onci.23849","journal-title":"Oncoimmunology"},{"issue":"11","key":"2070_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109699","volume":"36","author":"H Banerjee","year":"2021","unstructured":"Banerjee H, Nieves-Rosado H, Kulkarni A, Murter B, McGrath KV, Chandran UR, Chang A, Szymczak-Workman AL, Vujanovic L, Delgoffe GM, Ferris RL, Kane LP (2021) Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep 36(11):109699. https:\/\/doi.org\/10.1016\/j.celrep.2021.109699","journal-title":"Cell Rep"},{"issue":"9","key":"2070_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007474","volume":"11","author":"WJ Jin","year":"2023","unstructured":"Jin WJ, Zangl LM, Hyun M, Massoud E, Schroeder K, Alexandridis RA, Morris ZS (2023) ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models. J Immunother Cancer 11(9):e007474. https:\/\/doi.org\/10.1136\/jitc-2023-007474","journal-title":"J Immunother Cancer"},{"key":"2070_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","volume":"619","author":"AVR Kornepati","year":"2023","unstructured":"Kornepati AVR, Rogers CM, Sung P, Curiel TJ (2023) The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature 619:475\u2013486. https:\/\/doi.org\/10.1038\/s41586-023-06069-6","journal-title":"Nature"},{"key":"2070_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA, Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:409\u2013425. https:\/\/doi.org\/10.1038\/nrc3958","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"2070_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184383","volume":"14","author":"T Kimura","year":"2022","unstructured":"Kimura T, Fujiwara T, Kameoka T, Adachi Y, Kariya S (2022) The current role of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC). Cancers (Basel) 14(18):4383. https:\/\/doi.org\/10.3390\/cancers14184383","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2070_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/jgh.15319","volume":"36","author":"KJ Kim","year":"2021","unstructured":"Kim KJ, Lee HW, Seong J (2021) Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. J Gastroenterol Hepatol 36(5):1357\u20131365. https:\/\/doi.org\/10.1111\/jgh.15319","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2070_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3322\/caac.21713","volume":"72","author":"SP Rowe","year":"2022","unstructured":"Rowe SP, Pomper MG (2022) Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin 72(4):333\u2013352. https:\/\/doi.org\/10.3322\/caac.21713","journal-title":"CA Cancer J Clin"},{"key":"2070_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.addr.2014.07.009","volume":"76","author":"SY Lee","year":"2014","unstructured":"Lee SY, Jeon SI, Jung S, Chung IJ, Ahn CH (2014) Targeted multimodal imaging modalities. Adv Drug Deliv Rev 76:60\u201378. https:\/\/doi.org\/10.1016\/j.addr.2014.07.009","journal-title":"Adv Drug Deliv Rev"},{"key":"2070_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3950\/jibiinkoka.116.933","volume":"116","author":"I Umeda","year":"2013","unstructured":"Umeda I, Fujii H (2013) Current status and future prospect on molecular imaging for diagnosis and therapy. Nihon Jibiinkoka Gakkai Kaiho 116:933\u2013940. https:\/\/doi.org\/10.3950\/jibiinkoka.116.933","journal-title":"Nihon Jibiinkoka Gakkai Kaiho"},{"key":"2070_CR18","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1158\/1078-0432.Ccr-16-0437","volume":"23","author":"LE Lamberts","year":"2017","unstructured":"Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG et al (2017) Tumor-specific uptake of fluorescent Bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin Cancer Res 23:2730\u20132741. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0437","journal-title":"Clin Cancer Res"},{"key":"2070_CR19","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1158\/1078-0432.Ccr-14-3284","volume":"21","author":"EL Rosenthal","year":"2015","unstructured":"Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M et al (2015) Safety and tumor specificity of Cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin Cancer Res 21:3658\u20133666. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-3284","journal-title":"Clin Cancer Res"},{"key":"2070_CR20","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1039\/d1bm00674f","volume":"9","author":"D Li","year":"2021","unstructured":"Li D, Yang M, Liang M, Mei C, Lin Y, Yang F et al (2021) C-Met-targeted near-infrared fluorescent probe for real-time depiction and dissection of perineural invasion and lymph node metastasis lesions in pancreatic ductal adenocarcinoma xenograft models. Biomater Sci 9:6737\u20136752. https:\/\/doi.org\/10.1039\/d1bm00674f","journal-title":"Biomater Sci"},{"key":"2070_CR21","doi-asserted-by":"publisher","first-page":"15560","DOI":"10.1021\/acsomega.9b01920","volume":"4","author":"YT Xiao","year":"2019","unstructured":"Xiao YT, Zhou C, Ye JC, Yang XC, Li ZJ, Zheng XB et al (2019) Integrin \u03b16-targeted positron emission tomography imaging of colorectal cancer. ACS Omega 4:15560\u201315566. https:\/\/doi.org\/10.1021\/acsomega.9b01920","journal-title":"ACS Omega"},{"key":"2070_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2022.339798","volume":"1206","author":"WL Jiang","year":"2022","unstructured":"Jiang WL, Wang WX, Wang ZQ, Tan M, Mao GJ, Li Y, Li C-Y (2022) A tumor-targeting near-infrared fluorescent probe for real-time imaging ATP in cancer cells and mice. Anal Chim Acta 1206:339798. https:\/\/doi.org\/10.1016\/j.aca.2022.339798","journal-title":"Anal Chim Acta"},{"issue":"45","key":"2070_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201804827","volume":"31","author":"W Wang","year":"2019","unstructured":"Wang W, Hu Z (2019) Targeting peptide-based probes for molecular imaging and diagnosis. Adv Mater 31(45):e1804827. https:\/\/doi.org\/10.1002\/adma.201804827","journal-title":"Adv Mater"},{"key":"2070_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13238-019-0639-7","volume":"10","author":"PE Saw","year":"2019","unstructured":"Saw PE, Song EW (2019) Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein Cell 10:787\u2013807. https:\/\/doi.org\/10.1007\/s13238-019-0639-7","journal-title":"Protein Cell"},{"key":"2070_CR25","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/19420862.2016.1212149","volume":"8","author":"A Frenzel","year":"2016","unstructured":"Frenzel A, Schirrmann T, Hust M (2016) Phage display-derived human antibodies in clinical development and therapy. MAbs 8:1177\u20131194. https:\/\/doi.org\/10.1080\/19420862.2016.1212149","journal-title":"MAbs"},{"key":"2070_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215896","volume":"548","author":"S Ge","year":"2022","unstructured":"Ge S, Jia T, Li J, Zhang B, Deng S, Sang S (2022) Molecular imaging of immune checkpoints in oncology: current and future applications. Cancer Lett 548:215896. https:\/\/doi.org\/10.1016\/j.canlet.2022.215896","journal-title":"Cancer Lett"},{"key":"2070_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.addr.2020.06.012","volume":"167","author":"Y Ji","year":"2020","unstructured":"Ji Y, Jones C, Baek Y, Park GK, Kashiwagi S, Choi HS (2020) Near-infrared fluorescence imaging in immunotherapy. Adv Drug Deliv Rev 167:121\u2013134. https:\/\/doi.org\/10.1016\/j.addr.2020.06.012","journal-title":"Adv Drug Deliv Rev"},{"key":"2070_CR28","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1134\/s0006297919140037","volume":"84","author":"MM Karasev","year":"2019","unstructured":"Karasev MM, Stepanenko OV, Rumyantsev KA, Turoverov KK, Verkhusha VV (2019) Near-infrared fluorescent proteins and their applications. Biochemistry (Mosc) 84:S32-s50. https:\/\/doi.org\/10.1134\/s0006297919140037","journal-title":"Biochemistry (Mosc)"},{"issue":"4","key":"2070_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.201600335","volume":"17","author":"Z Qin","year":"2017","unstructured":"Qin Z, Wang J, Wang Y, Wang G, Wang X, Zhou Z, Liu G, Gao S, Zhu L (2017) Identification of a glypican-3-binding peptide for in vivo non-invasive human hepatocellular carcinoma detection. Macromol Biosci 17(4):1600335. https:\/\/doi.org\/10.1002\/mabi.201600335","journal-title":"Macromol Biosci"},{"key":"2070_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/acs.bioconjchem.6b00030","volume":"27","author":"D Zhu","year":"2016","unstructured":"Zhu D, Qin Y, Wang J, Zhang L, Zou S, Zhu X et al (2016) Novel glypican-3-binding peptide for in vivo hepatocellular carcinoma fluorescent imaging. Bioconjug Chem 27:831\u2013839. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00030","journal-title":"Bioconjug Chem"},{"key":"2070_CR31","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/hep.25777","volume":"56","author":"H Li","year":"2012","unstructured":"Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X et al (2012) Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56:1342\u20131351. https:\/\/doi.org\/10.1002\/hep.25777","journal-title":"Hepatology"},{"key":"2070_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature16969","volume":"531","author":"C Ma","year":"2016","unstructured":"Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P et al (2016) NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531:253\u2013257. https:\/\/doi.org\/10.1038\/nature16969","journal-title":"Nature"},{"key":"2070_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/187204","volume":"2013","author":"D Capece","year":"2013","unstructured":"Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E (2013) The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013:187204. https:\/\/doi.org\/10.1155\/2013\/187204","journal-title":"Biomed Res Int"},{"key":"2070_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40364-017-0106-7","volume":"5","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang Y (2017) Tumor-associated macrophages, potential targets for cancer treatment. Biomark Res 5:25. https:\/\/doi.org\/10.1186\/s40364-017-0106-7","journal-title":"Biomark Res"},{"key":"2070_CR35","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1136\/gutjnl-2014-307671","volume":"64","author":"W Yan","year":"2015","unstructured":"Yan W, Liu X, Ma H, Zhang H, Song X, Gao L et al (2015) Tim-3 fosters HCC development by enhancing TGF-\u03b2-mediated alternative activation of macrophages. Gut 64:1593\u20131604. https:\/\/doi.org\/10.1136\/gutjnl-2014-307671","journal-title":"Gut"},{"issue":"20","key":"2070_CR36","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1158\/0008-5472.Can-16-0549","volume":"76","author":"ME Rodriguez-Ruiz","year":"2016","unstructured":"Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bola\u00f1os E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I (2016) Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res 76(20):5994\u20136005. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-0549","journal-title":"Cancer Res"},{"issue":"4","key":"2070_CR37","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.Can-15-3142","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu C-G, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW (2017) Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res 77(4):839\u2013850. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-3142","journal-title":"Cancer Res"},{"key":"2070_CR38","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618. https:\/\/doi.org\/10.1038\/ncomms15618","journal-title":"Nat Commun"},{"issue":"7","key":"2070_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/hepr.12789","volume":"47","author":"D Friedman","year":"2017","unstructured":"Friedman D, Baird JR, Young KH, Cottam B, Crittenden MR, Friedman S, Gough MJ, Newell P (2017) Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma. Hepatol Res 47(7):702\u2013714. https:\/\/doi.org\/10.1111\/hepr.12789","journal-title":"Hepatol Res"},{"issue":"6","key":"2070_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.Cir-13-0115","volume":"1","author":"EB Golden","year":"2013","unstructured":"Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC (2013) An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1(6):365\u2013372. https:\/\/doi.org\/10.1158\/2326-6066.Cir-13-0115","journal-title":"Cancer Immunol Res"},{"key":"2070_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373\u2013377. https:\/\/doi.org\/10.1038\/nature14292","journal-title":"Nature"},{"issue":"17","key":"2070_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173016","volume":"16","author":"E Melia","year":"2024","unstructured":"Melia E, Parsons JL (2024) The potential for targeting G(2)\/M cell cycle checkpoint kinases in enhancing the efficacy of radiotherapy. Cancers (Basel) 16(17):3016. https:\/\/doi.org\/10.3390\/cancers16173016","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2070_CR43","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.263642","volume":"138","author":"R Seino","year":"2025","unstructured":"Seino R, Nishikubo K, Fukunaga H (2025) Cell cycle- and dose-dependent effects on mitochondrial DNA copy number variation following irradiation. J Cell Sci 138(15):jcs263642. https:\/\/doi.org\/10.1242\/jcs.263642","journal-title":"J Cell Sci"},{"key":"2070_CR44","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1200\/jco.20.03697","volume":"39","author":"M Hulshof","year":"2021","unstructured":"Hulshof M, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ et al (2021) Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO Study). J Clin Oncol 39:2816\u20132824. https:\/\/doi.org\/10.1200\/jco.20.03697","journal-title":"J Clin Oncol"},{"issue":"9","key":"2070_CR45","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1158\/1078-0432.Ccr-15-2246","volume":"22","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Murphy SJ, Peikert T, Yi ES, Vasmatzis G, Wigle DA, Aubry MC (2016) Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res 22(9):2177\u20132182. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2246","journal-title":"Clin Cancer Res"},{"key":"2070_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.609322","volume":"7","author":"L Zheng","year":"2020","unstructured":"Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q et al (2020) Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: a retrospective study. Front Mol Biosci 7:609322. https:\/\/doi.org\/10.3389\/fmolb.2020.609322","journal-title":"Front Mol Biosci"},{"key":"2070_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01157","volume":"9","author":"CL Chiang","year":"2019","unstructured":"Chiang CL, Chan ACY, Chiu KWH, Kong FS (2019) Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: a potential synergistic treatment strategy. Front Oncol 9:1157. https:\/\/doi.org\/10.3389\/fonc.2019.01157","journal-title":"Front Oncol"},{"key":"2070_CR48","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15:325\u2013340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29","journal-title":"Nat Rev Clin Oncol"},{"key":"2070_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W (2018) Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 18:195\u2013203. https:\/\/doi.org\/10.1038\/nri.2017.145","journal-title":"Nat Rev Immunol"},{"key":"2070_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106663","volume":"85","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Rezaeyan A, Najafi M (2020) Abscopal effect in radioimmunotherapy. Int Immunopharmacol 85:106663. https:\/\/doi.org\/10.1016\/j.intimp.2020.106663","journal-title":"Int Immunopharmacol"},{"key":"2070_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","volume":"12","author":"A Li","year":"2019","unstructured":"Li A, Yi M, Qin S, Song Y, Chu Q, Wu K (2019) Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol 12:35. https:\/\/doi.org\/10.1186\/s13045-019-0721-x","journal-title":"J Hematol Oncol"},{"key":"2070_CR52","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3171\/2022.9.Jns221036","volume":"138","author":"BM Dijkstra","year":"2023","unstructured":"Dijkstra BM, Nonnekens J, Nagengast W, Kruijff S, Meersma GJ, den Dunnen WFA et al (2023) Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery. J Neurosurg 138:1263\u20131272. https:\/\/doi.org\/10.3171\/2022.9.Jns221036","journal-title":"J Neurosurg"},{"key":"2070_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114697","volume":"193","author":"Y Yang","year":"2023","unstructured":"Yang Y, Xie Y, Zhang F (2023) Second near-infrared window fluorescence nanoprobes for deep-tissue in vivo multiplexed bioimaging. Adv Drug Deliv Rev 193:114697. https:\/\/doi.org\/10.1016\/j.addr.2023.114697","journal-title":"Adv Drug Deliv Rev"},{"key":"2070_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi3487","volume":"9","author":"DM Morgan","year":"2024","unstructured":"Morgan DM, Horton BL, Bhandarkar V, Van R, Dinter T, Zagorulya M et al (2024) Expansion of tumor-reactive CD8(+) T cell clonotypes occurs in the spleen in response to immune checkpoint blockade. Sci Immunol 9:eadi3487. https:\/\/doi.org\/10.1126\/sciimmunol.adi3487","journal-title":"Sci Immunol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02070-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02070-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02070-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:16:14Z","timestamp":1772817374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02070-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02070-9","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}